Alaunos Therapeutics, Inc.

Stage 4 · Declining · week 22

As of Oct 22, 2026, Alaunos Therapeutics is in Stage 4, the downtrend phase, now in week 22 (since May 18, 2026). It closed at $3.04, 30.3% below its 52-week high and above its 200-day average, which is falling.

$3.04

-1.30% today

$8.9M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is TCRT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 22w

S4 52w

S2 14w

S4 23w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 22w → S1 11w → S4 52w → S1 5w → S2 14w → S3 5w → S4 3w → S1 1w → S2 14w → S3 3w → S4 7w → S1 1w → S2 3w → S3 1w → S4 23w current

Total tracked: 165 weeks across 15 stage runs.

TCRT among Biotechnology153rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…153	TCRTAlaunos Therapeutics, Inc.	Stage 4 · wk 22	62	+164.3%

vs 52W High

-30.3%

$0.74 lo$4.36 hi

30.3% below 52W high, ongoing decline

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 22

1w13w26w

Week 22, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

28.8%

200 DMA: $2.36 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.15x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↑ ⇈

Short-term trend rising strongly, and accelerating

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+164.3%

+56.7%

+10.1%

YTD

-7.3%

+9.7%

Scan Membership

Breakout Watch

Latest: 2025-05-14

4 appearances in last 60 days. First seen: 2019-03-27.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 22 · Vol 0.15x

2026-10-21S4

Wk 22 · Vol 0.27x

2026-10-20S4

Wk 22 · Vol 0.40x

2026-10-19S4

Wk 22 · Vol 4.81x

2026-10-16S4

Wk 22 · Vol 4.06x

2026-10-15S4

Wk 21 · Vol 2.20x

2026-10-14S4

Wk 21 · Vol 11.02x

2026-10-13S4

Wk 21 · Vol 236.32x

2026-10-12S4

Wk 21 · Vol 3.36x

2026-10-09S4

Wk 21 · Vol 0.05x

2026-10-08S4

Wk 20 · Vol 0.09x

2026-10-07S4

Wk 20 · Vol 0.31x

Moving averages & range

50 DMA

$1.62

200 DMA

$2.36

52W High

$4.36

52W Low

$0.74

5D Low

$2.63

Resistance levels (recent highs)

20d High

$3.13

60d High

$3.13

120d High

$3.13

250d High

$4.36

Next resistance

+3.0%

to 20d High

ROE

-185.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 11.6

Alaunos Therapeutics: quick answers

What stage is Alaunos Therapeutics in?

As of Oct 22, 2026, Alaunos Therapeutics (TCRT) is in Stage 4, the downtrend phase. It entered Stage 4 on May 18, 2026 and is in week 22. What the four stages mean

Is Alaunos Therapeutics in an uptrend?

No. Alaunos Therapeutics is in a Stage 4 downtrend. It trades 28.8% above its 200-day average, which is falling.

How far is Alaunos Therapeutics from its 52-week high?

Alaunos Therapeutics closed at $3.04 on Oct 22, 2026, 30.3% below its 52-week high of $4.36. Its 52-week low is $0.74.

How has Alaunos Therapeutics performed over the past year?

As of Oct 22, 2026, Alaunos Therapeutics is up 9.7% over the past year and down 7.3% so far in 2026.

Which sector and industry is Alaunos Therapeutics in?

Alaunos Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.